Explore the 2026 Audience Breakdown
The rare and genetic kidney disease market is poised for significant growth, driven by expanding indications for existing therapies and advancements from companies like Travere, Calliditas, and Apellis, as the field shifts away from broad, one-size-fits-all kidney treatments and toward precision strategies tailored to distinct disease mechanisms and patient populations.
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston this August 18–20, as the only dedicated industry forum supporting rare renal therapies from discovery through to patients.
Attendee Profile Overview
This year, 50+ experts across biotechs, pharma, regulators and academics will gather to advance rare kidney disease treatment. Experts will convene across the drug development pipeline from R&D to commercialization.
See who is prioritizing their attendance this year.
Companies in the Room
This year, companies already in the room include:
- Alnylam Pharmaceuticals
- Bayer
- Critical Path Institute (C-Path)
- Deerfield Management
- Mironid
- National Kidney Foundation
- Novartis AG
- PKD Foundation
- Takeda Pharmaceutical
- Travere Therapeutics
- University of Arizona
- Vertex Pharmaceuticals
Explore the Agenda
Hear the latest breakthroughs in biomarker validation, surrogate endpoints, and clinical trial design through a packed agenda featuring 3 expert panel discussions, 3 pre-conference workshops, 2 interactive roundtables, and 12+ data-driven case study presentations.
Partner With Us
Position yourself alongside leading solution providers supporting rare and genetic kidney disease pipelines. Whether your expertise lies in preclinical or clinical research, novel biomarkers for diagnosis, stratification or monitoring, imaging, or genetic testing, ensure your brand is at the center of key conversations around clinical development, endpoint validation, and trial execution
Join Biopharma Experts
Engage with a uniquely focused audience of rare and genetic kidney disease decision-makers and be part of high-value conversations with like-minded attendees across all stages of drug development, building critical connections through dedicated networking opportunities